ArticleBiosensors2025
Possible Use of the SUDOSCAN Nephropathy Risk Score in Chronic Kidney Disease Diagnosis: Application in Patients with Type 2 Diabetes.
Article in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- GPIHBP1 as a Biomarker of Diabetic Polyneuropathy and Vascular Complications in Type 2 Diabetes Mellitus.Biomolecules · 2026Observational
- Circulating Neopterin Is Independently Associated with Autonomic Neuropathy in Type 2 Diabetes, but Not with Other Microvascular Complications.Medical sciences (Basel, Switzerland) · 2026Article
- An integrative analysis of cardiac autonomic neuropathy and nephropathy risk assessed with SUDOSCAN in individuals with type 2 diabetes.Frontiers in endocrinology · 2026Article
- Neonatal and Birth Risk Factors for Type 1 Diabetes Mellitus: Prediction Using an Artificial Neural Network.Life (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of quick and non-invasive techniques for detecting chronic kidney disease (CKD) in patients with type 2 diabetes mellitus is desirable and has recently garnered attention. One of these techniques is the evaluation of nephropathy risk based on electrochemical skin conductance (ESC) measured with a SUDOSCAN device. This paper aims to evaluate the possibility of using SUDOSCANs in chronic kidney disease prediction in diabetic patients and to investigate the relationships between clinical characteristics and SUDOSCAN parameters. The number of patients with type 2 diabetes included in this study was 254. Clinical metabolic characteristics like glycated hemoglobin, total and LDL cholesterol, triglyceride, blood pressure, and creatinine were determined along with body mass index, diabetes duration, and age. The estimated glomerular filtration rate (EGFR) was calculated and patients were grouped into three CKD stages based on EGFR values. Electrochemical skin conductance in hands and feet was determined with a SUDOSCAN device. The results showed that patients with symptomatic CKD (S2 and 3) presented lower ESC values, along with lower EFGRs and higher creatinine levels. A significant positive but weak correlation (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.